BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17482753)

  • 1. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study.
    Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
    Eur Urol; 2008 Jan; 53(1):106-11. PubMed ID: 17482753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 15-year followup of a population based prostate cancer screening study.
    Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
    J Urol; 2009 Apr; 181(4):1615-21; discussion 1621. PubMed ID: 19233435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
    Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH
    Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
    de Vries SH; Postma R; Raaijmakers R; Roemeling S; Otto S; de Koning HJ; Schröder FH
    Eur Urol; 2007 Feb; 51(2):366-74; discussion 374. PubMed ID: 16930812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway.
    Vatten LJ; Ursin G; Ross RK; Stanczyk FZ; Lobo RA; Harvei S; Jellum E
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):967-9. PubMed ID: 9367072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
    J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.